Numinus Wellness
Canadian mental healthcare company specializing in psychedelic-assisted therapies and innovative behavioral health treatments.
Stock Analysis – Numinus Wellness (TSX: NUMI)Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) is a Vancouver, British Columbia-based mental healthcare company founded in 2019. It focuses on delivering safe, evidence-based psychedelic-assisted therapies alongside traditional behavioral health services such as psychiatry, ketamine-assisted therapy (KAT), transcranial magnetic stimulation (TMS), medication management, and MDMA/psilocybin-assisted psychotherapy.
The company operates through three segments — Clinical Research Operations, Canadian Clinic Network, and U.S. Clinic Network — and conducts clinical trials involving substances such as LSD, MDMA, ketamine, psilocybin, and 5-MeO-DMT. Numinus also offers MAPS Protocol Training to certify practitioners in psychedelic-assisted therapy. In June 2022, it significantly expanded its footprint via the acquisition of U.S.-based Novamind for approximately C$26.2 million, bringing its combined network to 13 wellness clinics, four research sites, and one bioanalytical laboratory across North America.
More recently, Numinus entered a definitive agreement to sell its U.S. wellness clinics to Stella, an interventional psychiatry practice, while establishing a data partnership to develop a technology-driven clinic management solution for mental health providers. In Q4 Fiscal 2024, the company reported revenue of $1.2 million, a 16.4% increase over Q3 2024, reflecting early but growing commercial traction in a nascent and rapidly evolving sector.
Ideas that could help Numinus Wellness
- Psilocybin Depression Remission Clinic
A specialty outpatient clinic offering protocol-driven psilocybin-assisted therapy (25 mg sessions with structured psychological support) for patients with moderate-to-severe MDD or treatment-resistant depression who have not responded to SSRIs, backed by evidence of durable 12-month remission.
Why it helps: Numinus already operates psychedelic therapy clinics in North America and is building therapist training infrastructure, making them a direct operator of this protocol once regulatory approvals land.
- Psychedelic Therapy Protocol & Integration Platform
A clinical SaaS tool that standardizes the manualized psychological preparation, dosing-session monitoring, and post-session integration workflow required in every psychedelic-assisted therapy trial, enabling consistent, auditable delivery at scale.
Why it helps: Numinus operates a network of psychedelic therapy clinics and would benefit directly from a standardized protocol tool ensuring consistency, therapist training compliance, and outcome tracking across sites.